Abstract
The risk of lung cancer is high in patients with interstitial lung disease (ILD). It was reported that tumor markers was increased in ILD patients. The serum levels of CEA, CA19-9, CA125 and NSE were measured in 58 ILD combines lung cancer (ILD-CA) patients, 632 ILD patients and 632 control subjects. The analysis of covariance, multiple linear regression, Logistic regression analysis and ROC curve were used for statistical analyses. The serum levels of CEA, CA19-9, CA125 and NSE showed decrement tendency in ILD-CA group, ILD group and the control group (P <0.01). They were higher in patients with ILD-CA than those in patients with ILD and control (P <0.05). The levels of CEA and CA125 in ILD group were higher than the control group (P <0.01). The ILD group included idiopathic pulmonary fibrosis (IPF) subgroup of 214 cases, non-IPF idiopathic interstitial pneumonia (nonIPF-IIP) subgroup of 97 patients, collagen vascular disease associated ILD (CVD-ILD) subgroup of 163 cases, and other ILD subgroup of 158 cases. The serum levels of CEA, CA19-9 and CA125 were the highest in patients with IPF than the other three subgroups of ILD (P <0.01). Adjusting the confounding factors such as gender, age and smoking condition, the risk of ILD-CA increased with the elevation of CEA and CA125. This study provides that the elevation of serum tumor markers in patients with ILD-CA is a common sign, and is also an important sign in patients with ILD, especially in patients with IPF. Incidence of lung cancer is increased in ILD patients with elevation of the serum levels of CEA and CA125.
- © 2011 ERS